ELIQUIS – an oral, direct factor Xa inhibitor – is indicated for:
Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA); age ≥75 years; hypertension; diabetes mellitus; symptomatic heart failure (NYHA Class ≥II)1
Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults1
Prevention of venous thromboembolic events (VTE) in adult patients who have undergone elective hip or knee replacement surgery1
Please click here to access the ELIQUIS Patient Information Leaflet.
DVT = Deep Vein Thrombosis NVAF = Non-Valvular Atrial Fibrillation NYHA = New York Heart Association PE = Pulmonary Embolism TIA = Transient Ischaemic Attack VTE = Venous Thromboembolic Events
ELIQUIS® (apixaban) Summary of Product Characteristics.
You may contact our EU Data Protection Officer at EUDPO@BMS.com to exercise any data privacy rights that you may have, as well as to raise any concerns or questions in relation to the handling of your personal data by Bristol-Myers Squibb Company.
All corporate names and logos of BMS and/or of its products are trademarks of Bristol-Myers Squibb Company and are protected by national and international intellectual and industrial property laws. All rights reserved over the content of this website.